An “immune system reset” eliminated autoimmune, or Type 1, diabetes in mice in a study conducted at. Researchers say the strategy could also have potential for treating other autoimmune diseases and ...
Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...
MannKind Corporation (Nasdaq: MNKD) , a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung ...
New research to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) suggests that living in a rural environment ...
Management of CV risk factors and technology use in older adults with type 1 diabetes remains inconsistent despite high ASCVD prevalence.
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...
A large registry study in young people with type 1 diabetes found that hybrid closed-loop systems were linked to slightly better HbA1c and more time in the target glucose range than open-loop pump ...
This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. In 2024 Stephen Rich and his colleagues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results